Highest Risk QTc-Prolonging Agents

All categories
DBCAT002689Pharmacologic class

Drugs demonstrating a high risk of QTc interval prolongation in animal or human studies. A DrugBank category of 51 drugs. 50 of them are approved.

Part of
QTc Prolonging Agents
Also known as
High Risk QT Prolonging Agents · High Risk QT-Prolonging Agents · High Risk QTc-Prolonging Agents · Highest Risk QT Prolonging Agents · Highest Risk QT-Prolonging Agents
Drugs

and 26 more with a free account

What you can answer from here — as of January 03, 2019

51DrugsEach linked to its full drug card
Sign in
185Drug targetsEvery drug–target pair in the class, with bond type
Sign in
10,512Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
11Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Highest Risk QTc-Prolonging Agents share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In